The biotech industry is set to hit the ground running in 2015, with January alone bringing a passel of potentially stock-moving events by some of the biggest players. The second full week of the month will bring the annual JPMorgan Healthcare Conference in San Francisco, in which many companies release product and/or financial news. First thing on the morning of Jan. 12, Celgene (CELG) is set for a presentation. Typically the firm offers a preview
Celgene’s (CELG) drug Abraxane outperformed its predecessor in a large study of early-stage breast cancer, making its potential market bigger than previously thought, according to one analyst. Celgene stock was up 2% in morning trading in the stock market today. From the San Antonio Breast Cancer Symposium on Thursday, Leerink analyst Howard Liang wrote that a German study of 1,200 patients taking neoadjuvant chemotherapy (i.e., drug therapy
Big-cap biotechs Celgene (CELG) and Alexion Pharmaceuticals (ALXN) were both up in the stock market today after they beat analysts’ Q3 estimates and raised their guidance. Celgene’s Q3 earnings rose 24% over the year-earlier quarter to 97 cents a share, excluding one-time items, beating analysts’ estimates by 2 cents. Sales increased 18% to $1.98 billion, about $20 million above the Street’s forecast. Celgene guided full-year revenue at $7.6